Pacific Biosciences IPO
Pacific Biosciences (PacBio) develops and manufactures sequencing systems that enable scientists and clinical researchers to improve their understanding of the genome. The company is known for its long-read sequencing technology, which provides advantages in resolving complex genomic regions compared to short-read sequencing. PacBio's technology is used in genomics research, clinical diagnostics, and agricultural applications.
What We Know
Pacific Biosciences went public in October 2010, trading on NASDAQ under the ticker symbol PACB. The company's IPO raised approximately $200 million at $16 per share. Since going public, PacBio has focused on advancing its long-read sequencing technology and competing with other sequencing platforms in the genomics market. As a public company, PacBio has experienced significant stock price volatility, reflecting both the promise of its technology and the challenges of competing in the sequencing market dominated by Illumina. The company has continued to innovate and improve its sequencing platforms while working to expand its market share and achieve sustainable profitability.
Frequently Asked Questions
Has Pacific Biosciences had an IPO?
Yes, Pacific Biosciences has been a public company since October 2010. The company went public on NASDAQ under the ticker symbol PACB.
When is the Pacific Biosciences IPO date?
Pacific Biosciences completed its IPO in October 2010, raising approximately $200 million at $16 per share. The company has been publicly traded for over a decade.
How can I buy Pacific Biosciences stock?
You can buy Pacific Biosciences stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol PACB. The stock is available through standard online and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts